Claim Forms Available for Class Action Settlements Over Generic Drug Pricing

Fine, Kaplan and Black, R.P.C. announced that claim forms are now being accepted for class action settlements totaling over $533 million. Individuals and entities who paid for or were reimbursed for certain prescription generic drugs in the United States between May 1, 2009, and December 31, 2019, may be eligible to receive a payment.

The settlements resolve claims filed in the antitrust litigation known as In re Generic Pharmaceuticals Antitrust Litigation. The litigation alleged that generic drug manufacturers violated federal and state antitrust laws, leading to higher prices for consumers and third-party payers like insurers and employers. Several pharmaceutical companies, including Sandoz Inc., Fougera Pharmaceuticals Inc., Apotex Corp., Heritage Pharmaceuticals Inc., Sun Pharmaceutical Industries, Inc., and Taro Pharmaceuticals U.S.A., Inc., are parties to these settlements.

Settlement amounts include $275 million from Sandoz, $200 million from Sun/Taro, $10 million from Heritage, and $48 million from Apotex. These funds are intended to compensate consumers and third-party payers who indirectly purchased, paid for, or provided reimbursement for certain named generic drugs within the specified period and geographic areas, excluding Indiana and Ohio, along with some U.S. territories.

To receive a payment, eligible class members must submit a claim form with supporting documentation. The deadline for submitting claims, either online or by mail, is November 9, 2026. The amount of any payment will depend on the total number of valid claims filed and the amount spent on the covered drugs during the class period. After deducting administrative costs, attorney fees, and other expenses, the remaining funds will be distributed proportionally among eligible claimants.